As noted, NKCC1 inhibition by bumetanide has shown promise: in HD mice, bumetanide shifted E_GABA toward more hyperpolarized values, reduced excitability, and improved motor and cognitive outcomes [105]. This evidence concerns the gene SLC12A2 and Huntington disease.